There are several versions of generic versions of giritinib

The original drug Gilteritinib has been launched in many countries. It is understood that there are also many overseas countries producing generic drugs of Gilitinib. Its pharmaceutical ingredients are basically the same as those of the original drug and is suitable for the treatment of acute myeloid leukemia (Acute Myeloid Leukemia, AML) patients may have slight differences in production specifications and prices. Common manufacturers of gilitinib generics include Laos Lucius Pharmaceuticals, Daxiong Pharmaceutical Factory, etc. The price of a box of 40mg*84 tablets is around RMB 4,000 (the price may fluctuate due to exchange rate effects).

Treatment options for patients with relapsed/refractory acute myeloid leukemia (AML) have historically been limited. Treatment usually requires the use of high-dose salvage chemotherapy. Giritinib is a targeted therapy that offers an alternative for this high-risk population and has been shown to have better efficacy. Adverse effects mainly include elevated liver enzymes and cytopenias, although these can be effectively controlled. Giritinib provides a new treatment with controllable side effects for patients with FLT3-positive AML relapsed/refractory disease.

The original drug of geritinib has been launched in China, but it has not yet been included in the medical insurance. The price of each box of 40mg*42 tablets may be more than 20,000 yuan. The price of the Hong Kong version of the original drug is about 90,000 yuan per box. The price of the European version of the original drug, 40mg*84 tablets, per box listed overseas is around RMB 210,000 (the price may fluctuate due to exchange rates), which is very expensive. For more overseas drug information and specific prices, please consult Yaode Medical Consultant.